Stock IXC INVEX THERAPEUTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Invex Therapeutics Ltd

Equities

IXC

AU0000048621

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 03:26:51 08/05/2024 BST 		5-day change 1st Jan Change
0.078 AUD -7.14% Intraday chart for Invex Therapeutics Ltd -2.50% -3.70%
03-20 Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return MT
02-16 Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses MT

Valuation

Fiscal Period: June 2020 2021 2022 2023
Capitalization 1 87.75 47.35 37.2 15.03
Enterprise Value (EV) 1 61.45 14.63 7.862 -7.439
P/E ratio -21.7 x -20.7 x -9.41 x -1.94 x
Yield - - - -
Capitalization / Revenue - - 204 x 32.7 x
EV / Revenue - - 43.1 x -16.2 x
EV / EBITDA - - - -
EV / FCF 51,037,825,581 x -6,575,540 x -4,037,550 x 1,660,230 x
FCF Yield 0% -0% -0% 0%
Price to Book 3.6 x 1.48 x 1.31 x 0.71 x
Nbr of stocks (in thousands) 67,500 75,154 75,154 75,154
Reference price 2 1.300 0.6300 0.4950 0.2000
Announcement Date 27/08/20 26/08/21 18/08/22 17/08/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023
Net sales 1 0.000396 - - 0.1823 0.4591
EBITDA - - - - -
EBIT 1 -0.3811 -3.249 -2.443 -4.033 -8.547
Operating Margin -96,227.27% - - -2,212.89% -1,861.73%
Earnings before Tax (EBT) 1 -0.6964 -3.36 -2.284 -3.953 -7.75
Net income 1 -0.6964 -3.36 -2.284 -3.953 -7.75
Net margin -175,850% - - -2,169.06% -1,688.11%
EPS 2 -0.0295 -0.0598 -0.0304 -0.0526 -0.1031
Free Cash Flow - 0.001204 -2.225 -1.947 -4.481
FCF margin - - - -1,068.4% -976.07%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 27/08/19 27/08/20 26/08/21 18/08/22 17/08/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 12.2 26.3 32.7 29.3 22.5
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - 0 -2.23 -1.95 -4.48
ROE (net income / shareholders' equity) - -18.8% -8.09% -13.1% -31.2%
ROA (Net income/ Total Assets) - -10.5% -5.16% -8.1% -20.4%
Assets 1 - 32.09 44.25 48.79 37.93
Book Value Per Share 2 0.4800 0.3600 0.4300 0.3800 0.2800
Cash Flow per Share 2 0.5200 0.3900 0.4400 0.3900 0.3000
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 27/08/19 27/08/20 26/08/21 18/08/22 17/08/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INVEX THERAPEUTICS LTD Stock Invex Therapeutics Ltd
-3.70% 3.87M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IXC Stock
  4. Financials Invex Therapeutics Ltd